---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-267147"
form_type: "8-K"
ticker: "PCVX"
cik: "0001649094"
company_name: "Vaxcyte, Inc."
filed_at: "2022-10-24T23:59:59+00:00"
generated_at: "2026-06-23T01:39:42.976627+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Vaxcyte VAX-24 Phase 1/2 meets all endpoints; 2.2mcg dose advances to Phase 3

## Summary
- VAX-24 safety profile similar to Prevnar 20 at all doses; no related SAEs or chronic illnesses.
- All 24 serotypes met/exceeded regulatory immunogenicity standards at 2.2mcg dose.
- Of 20 serotypes common with PCV20, 16 showed higher OPA immune responses; 4 reached statistical significance.
- All 4 unique serotypes (2, 9N, 17F, 20B) exceeded standard superiority criteria at all doses.
- Milestones: Phase 3 adult data expected 2025; infant Phase 2 initiation in H1 2023; VAX-XP (31-valent) IND in H2 2023.

## SEC filing metadata
- accession: 0001193125-22-267147
- form_type: 8-K
- ticker: PCVX
- cik: 0001649094
- company_name: Vaxcyte, Inc.
- filed_at: 2022-10-24T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649094/000119312522267147/0001193125-22-267147-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649094/000119312522267147/d413834d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-267147
- JSON: https://secwatch.observer/filing/0001193125-22-267147.json
- Plain text: https://secwatch.observer/filing/0001193125-22-267147.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.